Global Oligonucleotide Therapeutics Market Surpasses $5 Billion in 2024, Driven by Strong Growth in siRNA and ASO Products

▎Armstrong

In 2024, the global small nucleic acid drug market size reached 5.092 billion US dollars, increasing by 18% year-on-year.

Alnylam's TTR product line sales maintained rapid growth, with total sales reaching $1.224 billion in 2024, a year-over-year increase of 34%.

Alnylam Rare Disease Product Line Sales Reach $423 Million, Up 29% Year-over-Year.

Spinraza's sales in 2024 reached $1.573 billion, showing a decline compared to 2023.

Ionis's revenue mainly comes from the royalties of Spinraza and the licensing to AstraZeneca. After Wainua's launch, sales began to increase rapidly, reaching 85 million U.S. dollars in 2024.

Sarepta’s PMO product line achieved $967 million in sales in 2024, showing a slight increase compared to 2023, while its AAV gene therapy Elevidys generated a whopping $821 million in sales.

Novartis' PCSK9 siRNA Therapy Leqvio Achieves $754 Million in Sales for 2024, Doubling Its 2023 Performance.

Summary

In the next few years, several small nucleic acid drugs are expected to be approved for marketing, including hepatitis B ASOs. The expansion into common diseases will drive the emergence of multiple blockbuster products in the small nucleic acid drug category. Additionally, AOC products are gradually entering pivotal clinical trials, and significant clinical breakthroughs are anticipated in the coming years.